EU approves Teizeild for patients with stage 2 type 1 diabetes – Sanofi
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and… read more.
The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and… read more.
Bayer announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients… read more.
HutchMed highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (Orpathys) and osimertinib (Tagrisso )… read more.
CMR Surgical the global surgical robotics business, announce that it has received CE and UKCA Marks for its Versius Surgical System (Versius) in paediatric surgery, marking the Company’s… read more.
Abbott unveiled Libre Assist, a groundbreaking feature within the Libre app designed to help the millions of people living with diabetes in the U.S. better understand how the foods… read more.
The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton’s tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who… read more.
Chemists at Ben-Gurion University of the Negev have developed a “smart” polymer that could make industrial curing, 3D printing and repairs simpler, safer and more energy-efficient with materials… read more.
Novo Nordisk announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and… read more.
Orexo AB announced the signing of an agreement with Dexcel Pharma to divest the full US rights to Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, for the treatment of opioid… read more.
Idorsia announced the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insights from a randomized controlled trial”… read more.
Arrowhead Pharmaceuticals, Inc. announced that the Chinese National Medical Products Administration (NMPA) has approved Redemplo (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia… read more.
Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.